Imagen de Portada

Liberty on Odaiba, Against the Silhouette of Tokyo Bay: Inspirations for Moving Hypothesis‐Generating Research to Patient‐Centered Therapeutics

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Karthik Venkatakrishnan
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Moving the Needle for Oncology Dose Optimization: A Call for Action
por: Karthik Venkatakrishnan, et al.
Publicado: (2024)

Innovations in Clinical Pharmacology: Shaping the Future of Evidence Generation in Research, Development, and Utilization of Medicines
por: Karthik Venkatakrishnan, et al.
Publicado: (2025)

Getting the Dosage Right: A Vital Role for Clinical Pharmacology in the Era of Precision Medicine
por: Iris K. Minichmayr, et al.
Publicado: (2024)

The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making
por: Mary Summer Starling, et al.
Publicado: (2024)

Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement
por: Irina Kareva, et al.
Publicado: (2025)

A Translational Model‐Based Meta‐Analysis to Predict Tremor Incidence Associated with Serotonin Reuptake Transporter Inhibition
por: Sheetal K. Panday, et al.
Publicado: (2025)

New Horizons for Clinical Pharmacology & Therapeutics : Global Outreach for Optimal Patient Outcomes
por: Karen Rowland Yeo
Publicado: (2025)

Pharmacokinetic Modeling and Model‐Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome
por: Fei Tang, et al.
Publicado: (2024)

Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials.gov
por: Lars Masanneck, et al.
Publicado: (2024)

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate
por: Ko‐Hsiu Lu, et al.
Publicado: (2026)

American Society for Clinical Pharmacology and Therapeutics
Publicado: (2026)

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation
por: Moherndran Archary, et al.
Publicado: (2026)

Quantitative Lesion‐Level Modeling Reveals Organ‐Dependent Therapeutic Response
por: Ian Dilley, et al.
Publicado: (2026)

Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
por: Divya Samineni, et al.
Publicado: (2024)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails
por: Niels A. D. Guchelaar, et al.
Publicado: (2024)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
por: Jatinder Kaur Mukker, et al.
Publicado: (2025)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
por: Mark J. Ratain
Publicado: (2024)

Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins
por: Yow‐Ming C. Wang, et al.
Publicado: (2024)

Current Status and Future Directions in the Development of Digital Therapeutic Interventions for Neurodevelopmental Disorders
por: Hyun‐ju Lee, et al.
Publicado: (2025)

Impact of Chronic Inflammatory Diseases on Clinical Pharmacokinetics of Antibody‐Based Therapeutic Proteins
por: Xiaofan Tian, et al.
Publicado: (2024)

Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial
por: Hung‐Kuan Yen, et al.
Publicado: (2025)

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies
por: Rachel K. Scott, et al.
Publicado: (2026)

Demonstration of Major Therapeutic Advantage From a Review of EU Conditional Marketing Authorizations in Oncology and Hematology
por: Florian Lasch, et al.
Publicado: (2025)

Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data
por: Mohammadali Alidoost, et al.
Publicado: (2025)

Questioning the Design of Non‐Inferiority Trials: The Strange Case for Therapeutic Drug Monitoring Absence in Phase III Trials
por: Florian Lemaitre, et al.
Publicado: (2024)

Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement
por: Abdelrahman Saqr, et al.
Publicado: (2025)

Innovations and Best Practices for Therapeutic Development in Pediatric Rare Diseases: A Model‐Informed Drug Development Perspective
por: Rajesh Krishna, et al.
Publicado: (2025)

Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and Vaccine Development: Bridging Translational and Platform Gaps for Enhanced Decision Making
por: Linh M. Van, et al.
Publicado: (2025)

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data
por: Michael I. Sponfeldner, et al.
Publicado: (2025)

Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low‐Risk Modalities?
por: Yusheng Qu, et al.
Publicado: (2024)

TMDD Modeling for Antibodies Directed Against Soluble Targets: Parameter Values for De Novo Modeling and Simulation From Experimental Data
por: Adam Nasim, et al.
Publicado: (2026)

Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
por: Annie Lumen, et al.
Publicado: (2024)

Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned
por: Tyler Shugg, et al.
Publicado: (2024)

The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression
por: Gia Han Le, et al.
Publicado: (2026)

Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies
por: Ameet Sarpatwari, et al.
Publicado: (2025)

Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients
por: Amy Rieborn, et al.
Publicado: (2025)

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma
por: Ruben Malmberg, et al.
Publicado: (2025)

Optimal Trough Concentration of Tacrolimus in Pediatric Patients With Primary Nephrotic Syndrome
por: Hui Wang, et al.
Publicado: (2024)

Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
por: Pamela Navarro‐Gonzales, et al.
Publicado: (2024)

Gut Microbiota in Patients with Tuberculosis Associated with Different Drug Exposures of Antituberculosis Drugs
por: Yue Zhu, et al.
Publicado: (2025)